
The New England Journal of Medicine | Research & Review Articles on ...
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous ...
Mar 11, 2026 · Apixaban and rivaroxaban are the oral anticoagulants most frequently used to treat acute venous thromboembolism. However, uncertainty remains about the difference in bleeding risk …
Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute ...
Mar 28, 2026 · Whether anticoagulation alone is an adequate treatment for acute, intermediate-risk pulmonary embolism is uncertain. We conducted a multinational, adaptive-design trial with blinded …
Romiplostim versus Placebo for Chemotherapy-Induced …
Mar 11, 2026 · Chemotherapy-induced thrombocytopenia (CIT) is a common complication of chemotherapy that is associated with bleeding, reduced relative dose intensity, and potentially worse …
Discontinuation of Beta-Blocker Therapy after Myocardial Infarction ...
Mar 30, 2026 · The role of long-term beta-blocker therapy after a myocardial infarction in patients without left ventricular systolic dysfunction or heart failure is unclear in the era of contemporary …
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple …
Dec 9, 2025 · In a phase 1–2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated …
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
Feb 18, 2026 · Patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy proceed directly to radical cystectomy with pelvic lymph-node dissection. …
Medical Management and Revascularization for Asymptomatic Carotid ...
Nov 21, 2025 · Improvements in medical therapy, carotid-artery stenting, and carotid endarterectomy call into question the preferred management of asymptomatic carotid stenosis. Whether adding …
Transdermal Estradiol Patches in Locally Advanced Prostate Cancer
Mar 25, 2026 · Transdermal estradiol (tE2) is an alternative to luteinizing hormone–releasing hormone (LHRH) agonists as androgen-deprivation therapy in patients with prostate cancer. With tE2, …
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for …
Sep 16, 2025 · Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity.